Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

The present disclosure provides a reaction of a chlorine-containing compound using a flow reactor which is less restricted by a solvent to be used. In the present disclosure, an organic compound is produced by supplying a reaction substrate having at least one functional group which can react with chlorine and is selected from the group consisting of hydroxy group, a thiol group, an amino group, a carboxyl group, a thiocarboxyl group, and an acid amide group, and a chlorine-containing compound to a flow reactor together with a trialkyl amine having 9 to 40 carbon atoms and an organic solvent, and allowing the reaction substrate and the chlorine-containing compound to react with each other.

The present disclosure provides a reaction of a chlorine-containing compound using a flow reactor which is less restricted by a solvent to be used. In the present disclosure, an organic compound is produced by supplying a reaction substrate having at least one functional group which can react with chlorine and is selected from the group consisting of hydroxy group, a thiol group, an amino group, a carboxyl group, a thiocarboxyl group, and an acid amide group, and a chlorine-containing compound to a flow reactor together with a trialkyl amine having 9 to 40 carbon atoms and an organic solvent, and allowing the reaction substrate and the chlorine-containing compound to react with each other.

The present invention relates to a compound obtained by a process comprising the following steps: (i) Reacting at least one isocyanate containing compound, in stoichiometric excess, with at least one isocyanate-reactive compound having a number average molecular weight equal to or higher than 400, resulting in the formation of at least one prepolymer having soft blocks and hard blocks in its structure, which prepolymer contains unreacted isocyanate monomer, (ii) Reacting said at least one prepolymer with a hydroxyl-ester compound or a hydroxyl-acid compound with the formation of hydroxyl-ester terminated prepolymer or hydroxyl-acid terminated prepolymer, and Ring-closing said hydroxyl-ester terminated prepolymer or hydroxyl-acid terminated prepolymer; (iii) Formation of said compound made of oxazolidinedione-terminated prepolymer and oxazolidinedione-terminated monomer, which is soluble in said oxazolidinedione-terminated prepolymer.

The present invention relates to a compound obtained by a process comprising the following steps: (i) Reacting at least one isocyanate containing compound, in stoichiometric excess, with at least one isocyanate-reactive compound having a number average molecular weight equal to or higher than 400, resulting in the formation of at least one prepolymer having soft blocks and hard blocks in its structure, which prepolymer contains unreacted isocyanate monomer, (ii) Reacting said at least one prepolymer with a hydroxyl-ester compound or a hydroxyl-acid compound with the formation of hydroxyl-ester terminated prepolymer or hydroxyl-acid terminated prepolymer, and Ring-closing said hydroxyl-ester terminated prepolymer or hydroxyl-acid terminated prepolymer; (iii) Formation of said compound made of oxazolidinedione-terminated prepolymer and oxazolidinedione-terminated monomer, which is soluble in said oxazolidinedione-terminated prepolymer.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.